Start practising

PassthePSA › PSA exam guide › Communicating Information

PSA section 4 of 8

Communicating Information

Pick the single most important thing this patient must know about their medicine. Several options may be true; one is the one that prevents harm.

The official PSA FAQ describes this section as providing information about medicines.

items in the paper
6
marks each
2
marks for the section
12 of 200
per item at exam pace
1 min 12 s

Video walkthrough

Communicating Information worked through on the exam interface, with the BNF open, in 9 min.

PSA Providing Information: Missed Doses, Warning Signs, Timing | Section 4 of 89 minWatch on YouTube

At a glance

Question styleSingle best answer from five
What you doSingle best answer from five
Primary skillPrioritising the safety-critical advice
BNF usePatient and carer advice, important safety information, warnings
On PassthePSASingle best answer in the exam's layout. 235 questions in this section, rated easy to hard.

What this section is really testing

  • Distinguishing information that prevents serious harm from information that is merely useful.
  • Knowing the specific warnings attached to specific drugs: the ones the BNF flags under important safety information and patient advice.
  • Reading the patient: pregnancy, driving, occupation, other medicines and the reason they were given the drug all change what matters most.
  • Resisting the clinic reflex of saying everything. The exam wants a ranking, not a list.

A repeatable approach

  1. Name the worst realistic harmFor this drug in this patient, what is the most serious thing that could go wrong?
  2. Ask what the patient must do or avoid to prevent itThat action is the candidate answer.
  3. Check the drug's specific warningsPatient and carer advice, and any important safety information box.
  4. Rank the remaining optionsSerious and specific beats general and practical.
  5. Choose oneThe option that, if unsaid, is most likely to end in harm.

Using the BNF for this section

The exam is open book, and the time is short. Know which heading answers which question before you open the monograph.

Drug→Important safety information→Patient and carer advice→Pregnancy / driving / other flags→The one thing to say
If you need to knowLook under
What must every patient on this drug be told?Patient and carer advice
Is there a regulator warning?Important safety information
Can they drive, drink, get pregnant?The monograph's cautions and pregnancy sections; driving under patient advice
What symptom means stop and seek help?Side-effects, and the advice attached to them

The general technique, with timed lookups, is in the BNF guide.

A hierarchy for ranking advice

When several options are true, rank them. The top of the hierarchy wins.

  1. 1Immediate serious harm: the warning that prevents a hospital admission or worse.
  2. 2An action the patient must take: report this symptom, do not stop suddenly, take it weekly not daily.
  3. 3A specific warning for this drug: sun, alcohol, driving, pregnancy.
  4. 4Routine practical advice: with food, at night, swallow whole.

Common traps

TrapWhy it costs marks
The useful over the vitalTake with food is true; report unexplained bruising is the mark.
Generic adviceOptions that apply to any drug rarely beat the warning specific to this one.
Forgetting the patientA warning about pregnancy matters more for a 24-year-old than a 74-year-old.
Reassurance as adviceTelling someone a side effect is common is not the same as telling them what to do about it.
The most frequent effectCommon is not the same as dangerous. Rank by harm, not by frequency.

Areas worth being comfortable with

Not predictions. These are the broad clinical areas this section draws on, taken from the shape of the exam and the BNF; being fluent in them makes the lookup fast.

  • Anticoagulants: bleeding, interactions and what to report
  • Antiepileptics and valproate in women of childbearing potential
  • Steroids: not stopping abruptly, sick-day rules, steroid cards
  • Methotrexate: weekly dosing and infection warnings
  • Opioids: sedation, driving, constipation and dependence
  • Antibiotics with alcohol or sun warnings
  • Inhaler technique and preventer versus reliever
  • Insulin and hypoglycaemia awareness
  • Lithium, digoxin and other narrow-margin drugs
  • Drugs that affect driving

What this section covers in the bank

Topics with the most communicating information questions at the last build, counted by the app's topic search; each link opens that topic in the app.

Worked examples

These are real questions from the PassthePSA bank, free to every visitor. Work each one with the BNF open before you show the answer; at exam pace a 2-mark item has 1 min 12 s.

What to tell a 60-year-old starting a weekly bisphosphonate

Communicating Information · COM-03 · 2 marks · medium

Case

A 60-year-old woman is started on an oral bisphosphonate for osteoporosis.

PMH: osteoporosis (T-score −2.6), gastro-oesophageal reflux disease.

DH: alendronic acid 70 mg PO once weekly (newly started), colecalciferol.

On examination: no dysphagia.

Investigations: corrected calcium 2.35 mmol/L (2.20–2.60), vitamin D replete.

Question

Select the most important instruction for taking this medicine.

(mark it with a tick)

Information options

  1. crush the tablet into a hot drink if it is hard to swallow whole
  2. take it in the middle of breakfast each week to avoid feeling sick
  3. take it last thing at night and stay lying down afterwards
  4. take it on an empty stomach with water, upright for 30 minutes
  5. take it with a large glass of milk to protect the stomach
Show the answer and markingHide the answer
Correct answer

take it on an empty stomach with water, upright for 30 minutes

Marks

2

Explanation

Oral bisphosphonates must be taken on an empty stomach with plenty of water, while sitting or standing upright for at least 30 minutes, to aid absorption and reduce the risk of oesophageal irritation. Two further points belong to this counselling and are commonly missed: calcium and vitamin D supplements, antacids and iron all bind the bisphosphonate in the gut, so they are taken at least 30 minutes after it, never at the same time; and new thigh, hip or groin pain should be reported, because it can rarely be the first sign of an atypical femoral fracture (MHRA Drug Safety Update, atypical femoral fractures with bisphosphonates). Because she has reflux disease, she should also be told to stop the tablet and seek advice if she develops new or worsening heartburn, pain on swallowing or difficulty swallowing.

© 2026 PassthePSA · Question COM-03 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

A 24-year-old with epilepsy offered a change to sodium valproate

Communicating Information · COM-19 · 2 marks · hard

Case

A 24-year-old woman with epilepsy attends the neurology clinic to discuss her treatment. She continues to have generalised tonic-clonic seizures despite a full dose of her current medicine, and a change to sodium valproate has been suggested.

PMH: generalised tonic-clonic epilepsy.

DH: levetiracetam 1 g PO twice daily (12-hrly); lamotrigine was stopped last year because of a widespread rash.

SH: sexually active with one partner; uses condoms only. Does not smoke.

On examination: well; BP 118/72 mmHg.

Investigations: a urinary pregnancy test today is negative.

Question

Select the most important information option that should be provided for the patient.

(mark it with a tick)

Information options

  1. an annual risk acknowledgement form is not needed once she is established on it
  2. it can be stopped abruptly at any time without risk of further seizures
  3. it is safe to continue in pregnancy provided high-dose folic acid is taken daily
  4. it must not be started unless two specialists agree there is no alternative
  5. it should be taken only when she feels a seizure starting to come on
Show the answer and markingHide the answer
Correct answer

it must not be started unless two specialists agree there is no alternative

Marks

2

Explanation

When deciding the most important information for this patient, start from the regulatory position rather than from the pharmacology. Following the MHRA Drug Safety Update of January 2024, valproate must not be started in any new patient younger than 55 years — female or male — unless two specialists independently consider and document that there is no other effective or tolerated treatment, or that the reproductive risks do not apply. This patient is 24 and of childbearing potential, so the conversation cannot begin with dosing or with side effects: it has to begin with the fact that starting valproate at all requires that second independent specialist opinion, alongside the pregnancy prevention programme, the annual risk acknowledgement form and highly effective contraception. Valproate exposure in utero carries a risk of major congenital malformation of about 11% and of neurodevelopmental disorder in up to 30–40% of children.

The remaining options are all false. Folic acid does not mitigate the malformation risk of valproate — the MHRA has said so explicitly — and valproate is not safe to continue in pregnancy. The annual risk acknowledgement form is not a one-off: it must be completed with a specialist at initiation and at every annual review for as long as treatment continues. Valproate is prophylactic and is taken regularly; it has no role taken at the onset of a seizure. And no antiepileptic is stopped abruptly — sudden withdrawal precipitates seizures and can precipitate status epilepticus, so any withdrawal is tapered under specialist supervision.

Further information: MHRA/CHM advice, 'Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age', January 2024; NICE NG217, Epilepsies in children, young people and adults.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question COM-19 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Before you submit

  • Have I ranked by harm rather than by how often I would say it?
  • Is my choice specific to this drug?
  • Does it fit this patient's age, pregnancy status and job?
  • Is there a regulator warning I have not considered?
  • Would the patient know what to do after hearing it?

Practise this section

Practise Communicating Information on its own, or meet it in exam proportions inside a full mock paper. The practice questions are written to reflect the PSA's format and marking closely; PassthePSA is independent of the assessment provider.

Practise Communicating Information questions 235 questions, each with a full explanation

Section sizes and marks follow the published PSA blueprint. The BNF headings named here are the current online BNF's. Check any dose or threshold against the BNF before you rely on it; this page teaches the method, the BNF holds the numbers.

Practise Communicating Information →